Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.

Authors: Dai, Bin  Hu, Zhiqiang  Huang, Hui  Zhu, Guangtong  Xiao, Zhiyong  Wan, Weiqing  Zhang, Peng  Jia, Wang  Zhang, Liwei 
Citation: Dai B, etal., Biochem Biophys Res Commun. 2014 Nov 7;454(1):221-7. doi: 10.1016/j.bbrc.2014.10.078. Epub 2014 Oct 22.
Pubmed: (View Article at PubMed) PMID:25450384
DOI: Full-text: DOI:10.1016/j.bbrc.2014.10.078

Epigenetic alterations such as aberrant expression of histone-modifying enzymes have been implicated in tumorigenesis. Upregulation of lysine (K)-specific demethylase 5B (KDM5B) has been reported in a variety of malignant tumors. However, the impact of KDM5B in glioma remains unclear. The objective of this study was to investigate the expression and prognostic value of KDM5B in glioma. In clinical glioma samples, we found that KDM5B expression was significantly upregulated in cancer lesions compared with normal brain tissues. Kaplan-Meier analysis showed that patients with glioma and higher KDM5B expression tend to have shorter overall survival time. By silencing or overexpressing KDM5B in glioma cells, we found that KDM5B could promote cell growth both in vitro and in vivo. Moreover, we demonstrated that KDM5B promoted glioma proliferation partly via regulation of the expression of p21. Our study provided evidence that KDM5B functions as a novel tumor oncogene in glioma and may be a potential therapeutic target for glioma management.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13702126
Created: 2018-07-17
Species: All species
Last Modified: 2018-07-17
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.